A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia
Paul J. Hampel(Mayo Clinic), Philip A. Thompson(The Royal Melbourne Hospital), Nitin Jain(Parul University), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Jonathan Hyak(The Ohio State University), Kerry A. Rogers(The Ohio State University), Erin M. Parry(Broad Institute), Mahesh Swaminathan(The University of Texas MD Anderson Cancer Center), Saad S. Kenderian(Mayo Clinic in Arizona), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Matthew S. Davids(Dana-Farber Cancer Institute), Wei Ding(Mayo Clinic), William G. Wierda(University of Maryland, Baltimore), Sameer A. Parikh(Mayo Clinic), Yucai Wang(Mayo Clinic), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 19
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k